BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
Healthcare
$1.86 -0.39%
-$0.03 today
- Market cap
- $149.27M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
52W Low $7.00High $14.87
Volume 0.37M
Average 0.37M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$145.82M
FY 2025 · Annual
Net Income
-$134.04M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| 20.49M | 20.49M | 20.49M | 16.64M | 31.14M | |
| 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BBOT Earnings Waterfall · TTM
NASDAQ:BBOT · Revenue to Net Income
Key Ratios
EPS$-5.71
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$154.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-5.71, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 23, 2026 |
How much revenue does BBOT generate?
BridgeBio Oncology Therapeutics Inc. (BBOT) reported $0.00 of revenue in fiscal 2025.
Is BBOT profitable?
BridgeBio Oncology Therapeutics Inc. (BBOT) reported -$134.04M of net income.
Continue the stock analysis
Jump to another research area for this company.